文献速递白血病

羟氯喹联合伊马替尼对照伊马替尼单药治疗主要细胞遗传学缓解但残留病灶的慢性髓性白血病随机II期试验

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
PubMed 文献 · Leukemia · 2020-01-10

12个月治疗成功率无差异,24个月联合组成功率提高20.8%但未达统计学显著,无患者进展。

要点

  • 12个月成功率两组无差异(p=0.58),MMR为80%对92%(p=0.21)。
  • 24个月联合组成功率提高20.8%(p=0.059),无患者进展。

核心结论

  • 伊马替尼联合羟氯喹在慢性期CML中可耐受,12个月和24个月qPCR水平有轻度改善,提示自噬抑制可能具有临床价值。

主要发现

  • 12个月治疗成功率两组无差异(p=0.58)。
  • 12个月MMR为伊马替尼组80%对联合组92%(p=0.21)。
  • 24个月联合组成功率提高20.8%(p=0.059),无患者进展。

关键数值与推荐

  • 主要终点为12个月qPCR水平较入组时下降≥0.5 log。
  • 次要终点包括24个月治疗成功率、12和24个月分子学缓解与进展、伊马替尼水平比较及血羟氯喹水平>2000 ng/ml的达成。

临床怎么用

  • 对主要细胞遗传学缓解但qPCR可检出残留病的慢性期CML患者,联合羟氯喹未在12个月显示成功率优势,24个月数值改善未达显著,需关注腹泻等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are responsible for disease persistence despite TKI. Based on in vitro data, CHOICES (CHlorOquine and Imatinib Combination to Eliminate Stem cells) was an international, randomised phase II trial designed to study the safety and efficacy of imatinib (IM) and hydroxychloroquine (HCQ) compared with IM alone in CP-CML patients in major cytogenetic remission with residual disease detectable by qPCR. Sixty-two patients were randomly assigned to either arm. Treatment 'successes' was the primary end point, defined as ≥0.5 log reduction in 12-month qPCR level from trial entry. Selected secondary study end points were 24-month treatment 'successes', molecular response and progression at 12 and 24 months, comparison of IM levels, and achievement of blood HCQ levels >2000 ng/ml. At 12 months, there was no difference in 'success' rate (p = 0.58); MMR was achieved in 80% (IM) vs 92% (IM/HCQ) (p = 0.21). At 24 months, the 'success' rate was 20.8% higher with IM/HCQ (p = 0.059). No patients progressed. Seventeen serious adverse events, including four serious adverse reactions, were reported; diarrhoea occurred more frequently with combination. IM/HCQ is tolerable in CP-CML, with modest improvement in qPCR levels at 12 and 24 months, suggesting autophagy inhibition maybe of clinical value in CP-CML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Horne GA, Stobo J, Kelly C, et al. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020. PMID: 31925317. doi:10.1038/s41375-019-0700-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。